Latest news

• Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO

  Novartis has revealed new data from a phase 3 trial evaluating its targeted radioligand therapy (RLT) in late stage advanced prostate cancer at the 2021 American Society of Clinical Oncology (ASCO) ... This] data from the first phase 3 study of a

• Novartis bolsters radioligand therapy pipeline with new licence agreement

  We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology. ... compared the radioligand therapy plus best standard of care (SoC) to SoC alone.

• Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

  Novartis’ investigational radioligand therapy 177Lu-PSMA-617 hit both primary endpoints in a phase 3 trial in patients with advanced prostate cancer. ... the radioligand therapy plus best standard of care (SoC) to SoC alone.

• Novartis reveals positive efficacy data for Xolair follow-up

  Next-generation treatment is more effective than current therapy. Novartis has data from a phase 2 study of its next-generation monoclonal antibody ligelizumab (QGE031), demonstrating superior efficacy compared to its ... Among the other promising

• Novartis highlights emerging assets and late-stage pipeline at R&D day

  Lu-PSMA-617, a radioligand therapy for prostate cancer which has phase 3 readouts due in the near future. ... It also has plans to expand wet AMD therapy  Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments  Piqray (alpelisib) and